Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amylin Pharmaceuticals and Alkermes have announced the availability of Bydureon (exenatide extended-release for injectable suspension) by prescription in the US pharmacies.
Subscribe to our email newsletter
Bydureon, once-weekly treatment for type 2 diabetes, was approved by FDA as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
The approval was based on safety and efficacy data from the DURATION clinical trial program, in which treatment with Bydureon resulted in improvements in glycemic control in a once-weekly dose.
Bydureon is provided in a straightforward single-dose tray so that patients can self-administer the once-weekly subcutaneous (under the skin) injection, the companies said.